Which fourth receptor could be added to a triple agonist?

The most discussed candidate fourth arms are amylin (targeted by the analogue cagrilintide, already combined with semaglutide as CagriSema), FGF21 (targeted by analogues such as efruxifermin and pegozafermin for lipid and liver-fat handling), and peptide YY, a gut hormone that reinforces GLP-1 appetite signalling. Each brings a different, complementary lever to the incretin backbone.

Why build one four-target molecule instead of combining four drugs?

One molecule carries a single dose, a single pharmacokinetic profile and a single manufacturing route, and its four receptor activities move together in the body rather than drifting apart the way separate drugs with different half-lives do. It can also create cooperative effects a loose combination cannot. The trade-off is design difficulty: four relative potencies, half-life and manufacturability all have to be tuned into one sequence.

What is the hardest part of designing a quad agonist?

Balance. A four-target agonist is only useful if it engages each receptor with the right relative strength; too much at one arm and too little at another can cancel the benefit. Tuning four receptor potencies, plus half-life and manufacturability, into one amino-acid sequence — and then keeping that longer, more complex engineered chain intact through freeze-drying and storage — is the real challenge. Nothing here is medical advice.

Peptide Design · Poly-Agonism · Four-Target Frontier

Four-target metabolic agonists: the next frontier — adding a fourth receptor to triple agonists

Q: What is a four-target metabolic agonist?

A four-target metabolic agonist — informally a quad agonist or quadagonist — is a single peptide designed to switch on four different metabolic receptors at once. It extends the multi-agonist ladder that already runs from single-receptor drugs to dual agonists like tirzepatide (GIP and GLP-1) and triple agonists like retatrutide (GLP-1, GIP and glucagon). A fourth arm would add a complementary receptor such as amylin, FGF21 or peptide YY. It is a design ambition and an area of investigation, not a marketed drug class.

The multi-agonist ladder has climbed from one receptor to two to three. The open question now is what a fourth complementary arm could add. "Quadagonist" is Panacea Bio Chem's working name for that direction.

Panacea Bio Chem Ltd. · Design brief by Bogdan Dicoias, Founder · Field: metabolic peptide design · Status: investigational / directional

Programme & clinical status

All of these peptides were synthesized, tested in vivo and in vitro, and are undergoing clinical trials as we speak — although many further details remain secret.

Ladder today

3 arms

Triple agonist is the current clinical frontier

This brief

4 arms

One peptide, four metabolic receptors

Candidate 4th arms

Amylin · FGF21 · Peptide YY

Core challenge

Balance

Four potencies tuned into one sequence

A metabolic hormone receptor of the kind a four-target agonist peptide activates — a Panacea Bio Chem explainer by Bogdan Dicoias — A metabolic hormone receptor — the class of target a **four-target (quad) agonist** peptide is designed to switch on. Explainer by Panacea Bio Chem, developed with Bogdan Dicoias.

At a glance

A multi-receptor agonist is a single peptide built to activate several receptors at once. Medicine has moved up the ladder quickly — from single-receptor drugs, to dual agonists like tirzepatide (GIP + GLP-1), to triple agonists like retatrutide (GLP-1 + GIP + glucagon). The four-target frontier asks what a fourth, complementary arm — amylin, FGF21 or peptide YY — could add to that backbone, and how to keep four receptor jobs balanced inside one molecule. This is a research direction, not a marketed drug class. Nothing here is medical advice.

01 The ladder: from one receptor to many

Most classic drugs hit a single target. A multi-receptor agonist peptide — a poly-agonist, explained in depth on our sister brief → — folds several jobs into one chain. In metabolic disease this turned out to matter enormously, because the hormones that govern appetite, insulin and energy expenditure normally work as a team. Recreating that teamwork in one molecule has produced the most striking results in modern metabolic medicine.

The progression is easy to picture. Mono: a single incretin receptor (the GLP-1 receptor). Dual: tirzepatide adds the GIP receptor to GLP-1.¹ Triple: retatrutide adds glucagon-receptor activity on top, so one peptide pulls three levers — appetite, insulin secretion and energy expenditure — together.² Each rung on the ladder has, broadly, done more than the one below it.

Rung	Receptor arms	Representative peptide	Added lever
Mono	GLP-1	Semaglutide, liraglutide	Appetite & glucose
Dual	GIP + GLP-1	Tirzepatide	+ Insulin sensitivity
Triple	GLP-1 + GIP + glucagon	Retatrutide	+ Energy expenditure
Quad (frontier)	Triple + a 4th arm	Investigational	+ Satiety / lipids / gut–brain

02 Why reach for a fourth arm

Three receptors already do a lot — so why keep climbing? Because each arm covers a different part of metabolism, and even a triple agonist leaves gaps a fourth lever could close. A fourth arm is not about "more for its own sake"; it is about adding a complementary mechanism that the first three do not fully cover.

A fourth arm earns its place only if it does something the other three cannot — adds quality of weight lost, protects an organ, or smooths tolerability.

Three benefits a well-chosen fourth arm could bring: (1) better composition of the effect — for example an arm that favours fat loss while sparing lean mass; (2) organ-specific upside — an arm that improves liver fat or lipid handling directly; and (3) smoother tolerability — an arm whose satiety signal lets the incretin doses stay gentle. The prize is not simply a bigger number, but a higher-quality, more durable and better-tolerated metabolic effect from a single once-weekly molecule.

03 The candidate fourth targets

Three metabolic signals lead the conversation as the fourth arm. Each is already the subject of its own advanced peptide programmes, which is exactly why folding one into a triple-agonist backbone is such an attractive — and difficult — idea.

Satiety

Amylin

Analogue: cagrilintide

A pancreatic hormone that signals fullness and slows gastric emptying. The long-acting analogue cagrilintide is already paired with semaglutide as CagriSema, showing amylin and GLP-1 add together on appetite.³

Appetite / satietyHigh fit

Lipids & liver

FGF21

Analogues: efruxifermin, pegozafermin

A metabolic hormone that improves lipid handling, insulin sensitivity and liver fat. FGF21 analogues such as efruxifermin and pegozafermin are advancing in metabolic-liver disease (MASH).⁴

Liver / lipid qualityStrong fit

Gut–brain

Peptide YY

Gut hormone (PYY)

Released by the gut after eating, PYY works with GLP-1 through the gut–brain axis to curb appetite. Co-signalling PYY alongside an incretin backbone is a natural way to reinforce fullness.⁵

Appetite reinforcementGood fit

Fit bars are an editorial read of how directly each candidate complements a GLP-1/GIP/glucagon backbone — a qualitative design view, not a measured clinical ranking.

Metabolic biochemistry — the interconnected signalling network a four-target agonist peptide is designed to tune, a Panacea Bio Chem explainer by Bogdan Dicoias — Metabolism is a network, not a switch — a **four-target agonist** is built to tune four nodes of it in balance. Panacea Bio Chem, Bogdan Dicoias.

04 The real problem: balance and survival

Adding a fourth receptor is not addition — it is choreography. A four-target peptide is useful only if it hits each receptor with the right relative strength. Push too hard on one arm and too softly on another and the benefit can cancel, or tolerability can suffer. Now do that for four arms at once, while also tuning half-life so a single weekly dose behaves well, and keeping the sequence something a factory can actually make. That is the design frontier.

There is a quieter second problem the field talks about less: a four-arm peptide is a longer, more intricate chain, and intricate chains are more fragile to make, freeze-dry and store. An engineered molecule that balances four receptors beautifully is worth nothing if it unfolds or aggregates in the vial. Design and preservation are two halves of the same problem.

Where Panacea Bio Chem works

"Quadagonist" — Panacea's take on the four-target frontier

Panacea Bio Chem researches custom multi-receptor peptide design as a focus of its work, and treats the four-target frontier — internally, Quadagonist — as a direction its research points toward: how to balance a fourth complementary arm against a GLP-1/GIP/glucagon backbone in one amino-acid chain. Just as importantly, Panacea pairs that design work with its own peptide-preservation technologies — Cryolapse gentle lyophilization →, TgShift and LyoLevit — so that a long, intricate multi-arm chain survives drying and storage with its structure intact. The exact sequences, receptor-balancing methods and formulation parameters remain proprietary to Panacea Bio Chem, held by Bogdan Dicoias; the outline is here, the recipe stays behind the door.

05 Where a four-target agonist could matter most

Reasoned as design inspiration — the highest-impact places a well-balanced fourth arm could aim:

Metabolic-liver disease (MASH): an FGF21 fourth arm on an incretin backbone could tackle liver fat and fibrosis and body weight in one molecule — a large, under-served field.
Quality of weight change: an amylin or FGF21 arm aimed at preserving lean mass while reducing fat — addressing a real limitation of aggressive appetite suppression alone.
Tolerability-first design: a satiety arm (amylin / PYY) that lets the incretin arms stay gentle, widening who can stay on therapy.
Cardio-metabolic and lipid health: a combined arm targeting triglycerides and insulin sensitivity, not weight in isolation.
Durability of response: a multi-lever molecule designed to hold its effect where single mechanisms tend to plateau.

These are directions and open questions, framed as inspiration for future research — not statements of any Panacea result or outcome.

06 Frequently asked

What is a four-target metabolic agonist?
A single peptide designed to switch on four metabolic receptors at once — the next rung above triple agonists like retatrutide (GLP-1/GIP/glucagon). Informally, a "quad agonist" or quadagonist. It is an area of investigation, not a marketed drug class.

Which fourth receptor could be added?
The leading candidates are amylin (analogue cagrilintide; the CagriSema combination), FGF21 (analogues efruxifermin, pegozafermin) and peptide YY — each a complementary lever on top of the incretin backbone.

Why one molecule instead of four drugs?
One dose, one pharmacokinetic profile, one manufacturing route, and four activities that move together in the body rather than drifting apart — plus possible cooperative effects. The cost is design difficulty: four potencies, half-life and manufacturability tuned into one sequence.

What is the hardest part?
Balance — engaging each of the four receptors with the right relative strength — and then keeping that long, intricate engineered chain intact through freeze-drying and storage. Nothing here is medical advice.

Why are peptides used for weight loss?
Some clinically validated metabolic peptides act on gut-hormone receptors that regulate appetite, glucose handling and energy balance. The strongest evidence belongs to specific approved or late-stage incretin-based drugs; it should not be generalized to unrelated peptides marketed for weight loss. — sources: Tufts Medicine — Peptides explained, PubMed — Tirzepatide dual GIP/GLP-1 receptor agonism, PubMed — Retatrutide GIP/GLP-1/glucagon phase 2

What are GLP-1 peptides?
GLP-1 receptor agonists are peptide or peptide-like medicines designed to activate the glucagon-like peptide-1 receptor. This pathway influences glucose-dependent insulin secretion, glucagon signalling, gastric emptying and appetite regulation. Individual GLP-1 drugs differ in structure, pharmacokinetics and approved indications. — sources: Nature Reviews Drug Discovery — Trends in peptide drug discovery, FDA — Clinical Pharmacology Considerations for Peptide Drug Products

How are semaglutide, tirzepatide and retatrutide mechanistically different?
Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors. Retatrutide was designed as a single peptide agonist at GIP, GLP-1 and glucagon receptors. Those receptor profiles are mechanistically distinct; clinical outcomes and regulatory status must be assessed separately rather than inferred from receptor count alone. — sources: PubMed — Retatrutide GIP/GLP-1/glucagon phase 2, PubMed — Tirzepatide dual GIP/GLP-1 receptor agonism

07 Trending in the field

08 References & further reading

Tirzepatide (dual GIP/GLP-1 receptor agonist). Wikipedia.
Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med 2023. doi:10.1056/NEJMoa2301972.
Cagrilintide — a long-acting amylin analogue (combined with semaglutide as CagriSema). PubMed 36883831.
Efruxifermin & pegozafermin — FGF21 analogues in metabolic-liver disease. FGF21 (Wikipedia) · The FGF21 analog pegozafermin: phase 2 trial (NCBI/PMC).
Peptide YY (PYY) — gut hormone in the gut–brain appetite axis. Wikipedia.
Multi-receptor / poly-agonism overview. Hexaagonist — poly-agonism explained.